Clinical Evaluation of Apoprotein A-I and A-II in Patients with Hepatobiliary Diseases

TAKATA KOKI, HINO FUMIAKI, YAMAMOTO MASAHARU, KAWAMOTO TOSHIO, OKAHASHI MAKOTO, OKI MASAMI, KAJIYAMA GORO

doi:10.14921/jscc1971b.12.4_319

The serum apoproteins A-I and A-II concentrations were determined in124 patients with hepatobiliary diseases and30normal subjects.The determination of these apoproteins by single radial immunodiffusion was highly corre-ated with that by electroimmunoassay.<BR>The mass of apoproteins A-I and A-II, the major proteins of high-density lipoprotein (HDL), decreased in many liver parenChymal diseases and obstructive jaundice. But, the ratio of apoprotein A-I to A-II increased only in the decompensated stage of liver cirrhosis and obstructive jaundice-The amounts of apoproteins A-I and A-II in hepatobi-iary diseases correlated with HDL3-cholesterol (d=1.063-1.125).The clinical course of apoproteins A-I and A-II in one patient with subacute hepatitis showed the discrepancy with HDL-cholesterol, and the histological findings of biopsy specimen were identifiable with the amounts of the former than that of the latter.The amounts of apoproteins A-I and A-II correlated strognly with conventional liver functional tests (e.9., albumin, choline-esterase, total protein, lecithin-cholesterol acyltransferase).<BR>These results indicate that apoproteins A-I and A-II are metabo-ized somewhat independently of each other and the lipid components in HDL.We must, therefore, measUre apoproteins as well as lipid moieties when -ooking at patlents with hepatobiliary diseases.

Clinical Evaluation of Apoprotein A-I and A-II in Patients with Hepatobiliary Diseases

Bibliographic Information

Abstract

Journal

Details 詳細情報について

Export

Report a problem